临床实践指南:发音障碍(声嘶)更新版执行摘要
该指南由美国耳鼻咽喉头颈外科学会基金会制定,针对各年龄段发音障碍患者提供循证推荐。指南强调病史和体格检查识别需加速喉评估的因素,推荐对适合的患者进行嗓音治疗,反对常规使用抗生素、未可视喉部前使用CT/MRI或抑酸药物。
要点
- 病史和体格检查应识别需加速喉评估的因素,如近期头颈胸手术、插管、颈部肿块、呼吸困难或喘鸣、吸烟史及专业嗓音使用者。
- 对适合嗓音治疗的发音障碍患者应推荐嗓音治疗。
- 发音障碍持续4周未缓解或怀疑严重病因时应行喉镜检查。
核心结论
- 指南基于当前最佳证据提出发音障碍的评估与治疗推荐,旨在减少不当差异、优化结局并最小化伤害。
研究设计与样本
- 美国耳鼻咽喉头颈外科学会基金会组建多学科专家组制定,纳入3项新指南、16项新系统评价和4项新随机对照试验。
主要发现
- 发音障碍影响近三分之一人群的一生。
- 指南更新组对2项关键行动声明做出强推荐,对8项做出推荐,对1项做出强反对,对3项做出反对,对1项做出可选推荐。
关键数值与推荐
- 强推荐:通过病史和体格检查识别需加速喉评估的因素,包括近期头颈胸手术、近期气管插管、伴颈部肿块、呼吸窘迫或喘鸣、吸烟史及是否专业嗓音使用者。
- 强推荐:对病因适合嗓音治疗的患者提倡嗓音治疗。
- 推荐:发音障碍持续4周未缓解或怀疑严重病因时行喉镜检查,不论持续时间。
- 推荐:处方嗓音治疗前应行诊断性喉镜检查并将结果告知言语语言病理学家。
- 强反对:不常规处方抗生素治疗发音障碍。
临床怎么用
- 临床医生应通过病史和体格检查评估发音障碍,识别需加速喉评估的因素。
- 对适合嗓音治疗的患者应提倡嗓音治疗,并在治疗前完成喉镜检查。
- 喉部未可视前不应常规处方抗生素、抑酸药物或皮质类固醇,也不应行CT或MRI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective This guideline provides evidence-based recommendations on treating patients presenting with dysphonia, which is characterized by altered vocal quality, pitch, loudness, or vocal effort that impairs communication and/or quality of life. Dysphonia affects nearly one-third of the population at some point in its life. This guideline applies to all age groups evaluated in a setting where dysphonia would be identified or managed. It is intended for all clinicians who are likely to diagnose and treat patients with dysphonia. Purpose The primary purpose of this guideline is to improve the quality of care for patients with dysphonia, based on current best evidence. Expert consensus to fill evidence gaps, when used, is explicitly stated and supported with a detailed evidence profile for transparency. Specific objectives of the guideline are to reduce inappropriate variations in care, produce optimal health outcomes, and minimize harm. For this guideline update, the American Academy of Otolaryngology-Head and Neck Surgery Foundation selected a panel representing the fields of advanced practice nursing, bronchoesophagology, consumer advocacy, family medicine, geriatric medicine, internal medicine, laryngology, neurology, otolaryngology-head and neck surgery, pediatrics, professional voice, pulmonology, and speech-language pathology. Action Statements The guideline update group made strong recommendations for the following key action statements (KASs): (1) Clinicians should assess the patient with dysphonia by history and physical examination to identify factors where expedited laryngeal evaluation is indicated. These include but are not limited to recent surgical procedures involving the head, neck, or chest; recent endotracheal intubation; presence of concomitant neck mass; respiratory distress or stridor; history of tobacco abuse; and whether the patient is a professional voice user. (2) Clinicians should advocate voice therapy for patients with dysphonia from a cause amenable to voice therapy. The guideline update group made recommendations for the following KASs: (1) Clinicians should identify dysphonia in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces quality of life (QOL). (2) Clinicians should assess the patient with dysphonia by history and physical examination for underlying causes of dysphonia and factors that modify management. (3) Clinicians should perform laryngoscopy, or refer to a clinician who can perform laryngoscopy, when dysphonia fails to resolve or improve within 4 weeks or irrespective of duration if a serious underlying cause is suspected. (4) Clinicians should perform diagnostic laryngoscopy, or refer to a clinician who can perform diagnostic laryngoscopy, before prescribing voice therapy and document/communicate the results to the speech-language pathologist (SLP). (5) Clinicians should advocate for surgery as a therapeutic option for patients with dysphonia with conditions amenable to surgical intervention, such as suspected malignancy, symptomatic benign vocal fold lesions that do not respond to conservative management, or glottic insufficiency. (6) Clinicians should offer, or refer to a clinician who can offer, botulinum toxin injections for the treatment of dysphonia caused by spasmodic dysphonia and other types of laryngeal dystonia. (7) Clinicians should inform patients with dysphonia about control/preventive measures. (8) Clinicians should document resolution, improvement or worsened symptoms of dysphonia, or change in QOL of patients with dysphonia after treatment or observation. The guideline update group made a strong recommendation against 1 action: (1) Clinicians should not routinely prescribe antibiotics to treat dysphonia. The guideline update group made recommendations against other actions: (1) Clinicians should not obtain computed tomography (CT) or magnetic resonance imaging (MRI) for patients with a primary voice complaint prior to visualization of the larynx. (2) Clinicians should not prescribe antireflux medications to treat isolated dysphonia, based on symptoms alone attributed to suspected gastroesophageal reflux disease (GERD) or laryngopharyngeal reflux (LPR), without visualization of the larynx. (3) Clinicians should not routinely prescribe corticosteroids in patients with dysphonia prior to visualization of the larynx. The policy level for the following recommendation about laryngoscopy at any time was an option: (1) Clinicians may perform diagnostic laryngoscopy at any time in a patient with dysphonia. Differences from Prior Guideline (1) Incorporating new evidence profiles to include the role of patient preferences, confidence in the evidence, differences of opinion, quality improvement opportunities, and any exclusion to which the action statement does not apply (2) Inclusion of 3 new guidelines, 16 new systematic reviews, and 4 new randomized controlled trials (3) Inclusion of a consumer advocate on the guideline update group (4) Changes to 9 KASs from the original guideline (5) New KAS 3 (escalation of care) and KAS 13 (outcomes) (6) Addition of an algorithm outlining KASs for patients with dysphonia.
引用
- Stachler RJ, Francis DO, Schwartz SR, et al. Clinical Practice Guideline: Hoarseness (Dysphonia) (Update) Executive Summary. Otolaryngol Head Neck Surg. 2018. PMID: 29494316. doi:10.1177/0194599817751031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。